The invention has the advantages of stable quality, controllability and safety
For professionals, training can be downright gruelingsometimes a literal exhaustion of blood, sweat, and tears
As the obesity epidemic continues to affect our beloved cats and dogs, causing a myriad of health issues including diabetes, there is an increasing demand for effective weight management solutions
We discuss: Medicare Bridge Program eligibility requirements Zepbound, Wegovy, Foundayo (orforglipron), and GLP-1 coverage updates BMI and comorbidity qualifications Prediabetes, sleep apnea, cardiovascular disease, and obesity treatment access How Medicare patients can obtain GLP-1 medications Why obesity is finally being treated as a chronic disease The future of obesity medicine and Medicare coverage Concerns about access to care vs access to medication Muscle loss, nutrition, strength training, and healthy weight loss The Treat and Reduce Obesity Act (TROA) This may be one of the most important developments in obesity treatment history, potentially opening the door for millions of Americans living with obesity, prediabetes, cardiovascular disease, and other weight-related conditions to receive evidence-based care
The FDA's shortage-based enforcement discretion periods for both semaglutide and tirzepatide compounding have ended, and the regulatory environment for compounded GLP-1 products continues to evolve
